A.I.DEMOCRATIC WOMEN ASSOCN vs U O I. Supreme Court, 16-03-1998

JudgeA.S. ANAND,S. RAJENDRA BABU,A.P. MISRA
Parties A.I.DEMOCRATIC WOMEN ASSOCNU O I
Date16 March 1998
Docket NumberW.P.(C) No.-000500-000500 / 1997
CourtSupreme Court (India)
http://JUDIS.NIC.IN SUPREME COURT OF INDIA Page 1 of 2
PETITIONER:
A.I. DEMOCRATIC WOMEN ASSOCIATION & ORS.
Vs.
RESPONDENT:
UNION OF INDIA & ANR.
DATE OF JUDGMENT: 16/03/1998
BENCH:
A.S. ANAND, S. RAJENDRA BABU, A.P. MISRA
ACT:
HEADNOTE:
JUDGMENT:
O R D E R
In this writ petition challenge is made to the use of
the drug ’Quinacrine’ as a method of female sterilisation.
Following prayer is made:
"a) To issue a writ of Mandamus or
any other appropriate writ, order
or direction directing respondent
nos. 1 and 2 to initiate immediate
steps to ban the use of Quinacrine
in the form of pellets or otherwise
as a method of sterilisation.
b) To issue a writ of Mandamus or
any other appropriate writ, order
or direction directing respondent
nos. 1 and 2 to initiate
proceedings under the Drugs and
Cosmetics Act, 1945 against all
those engaged in the importation
and/or manufacture, transmission,
sale and use of Quinacrine in the
form of pellets or otherwise as a
method of sterilisation.
c) To issue a writ of Mandamus or
any other appropriate writ, order
or direction directing respondent
nos. 1 and 2 to issue a
notification under Section 26A of
the Drugs and Cosmetics Act, 1945,
banning the use of Quinacrine as a
method of sterilisation."
Counter affidavit on behalf of respondent No.3 has been
filed in court today through Ms. Kamini Jaiswal. The same is
taken on record.
An affidavit has been filed by Shri Ashwine Kumar
working in the office of the Directorate General of Health
services as joint Drugs controller ( India).
Paragraph 3 of the affidavit reads thus:
" I say that the respondent is
taking necessary steps to invoke
the provisions of Sections 10-A and

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT